Characteristics and 6-Month Outcomes in Patients with Rheumatoid Arthritis Initiating Infliximab Biosimilar IFX-dyyb in a Real-World Setting
- Resource Type
- Article
- Authors
- Baker, Joshua F.; Bakewell, Catherine; Dikranian, Ara; Lam, Gordon; O’Brien, Jacqueline; Moore, Page C.; Yu, Miao; Hur, Peter; Masri, Karim R.
- Source
- Rheumatology and Therapy; June 2024, Vol. 11 Issue: 3 p841-853, 13p
- Subject
- Language
- ISSN
- 21986576; 21986584
Infliximab is an effective treatment for rheumatoid arthritis (RA). Biosimilars—biologic drugs designed to be very similar to the originator products—are now available that may be more affordable with matching efficacy and safety. IFX-dyyb is a US Food and Drug Administration-approved infliximab biosimilar but little is known about its use in real-world clinical practice in patients with RA in the USA. This study used data from a large observational registry to look at treatment patterns and effectiveness of IFX-dyyb in adults with RA. One hundred and seventy-six patients were included who had data available at both baseline and at 6 months. Most patients (47%) switched to IFX-dyyb from the originator infliximab or another infliximab biosimilar; 35% switched from another RA treatment, and 18% were new to treatment. Six months after starting IFX-dyyb, 68% of patients were still receiving treatment. A measure of clinical disease activity remained stable in patients who switched from originator infliximab or another biosimilar, while this measure improved in patients switching to IFX-dyyb from other treatments or starting treatment for the first time. Other clinical measures and patient-reported outcomes such as pain and fatigue also improved over 6 months with IFX-dyyb. This real-world study of patients with RA initiating IFX-dyyb in the USA adds to our knowledge of the use of biosimilars in this patient population.